A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation

Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic benefit based on nonclinical and emerging clinical findings. However, the eventual emergence of drug resistant tumors motivates the pre-emptive identification of potential mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Nathan V., Lira, Maruja E., Pavlicek, Adam, Ye, Jingjing, Buckman, Dana, Bagrodia, Shubha, Srinivasa, Sreesha P., Zhao, Yongjun, Aparicio, Samuel, Rejto, Paul A., Christensen, James G., Ching, Keith A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382171/
https://www.ncbi.nlm.nih.gov/pubmed/22745804
http://dx.doi.org/10.1371/journal.pone.0039653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382171/
https://www.ncbi.nlm.nih.gov/pubmed/22745804
http://dx.doi.org/10.1371/journal.pone.0039653

Ejemplares similares